5.95

1.71% 0.10

After Hours: 6.07 0.12 +2.02%

Relay Therapeutics Inc (RLAY)

Overview News Price History Option Chain Financials Why RLAY Down? Discussions Forecast

Relay Therapeutics Inc stock is traded at $5.95, with a volume of 1.04M. It is up +1.71% in the last 24 hours and down -8.88% over the past month. Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Previous Close:

$5.85

Open:

$5.78

24h Volume:

1.04M

Relative Volume:

0.55

Market Cap:

$966.65M

Revenue:

$25.55M

Net Income/Loss:

$-341.97M

P/E Ratio:

-2.2119

EPS:

-2.69

Net Cash Flow:

$-304.44M

1W Performance:

+0.85%

1M Performance:

-8.88%

6M Performance:

-15.48%

1Y Performance:

-20.88%

1-Day Range:

$5.66

$6.00

1-Week Range:

$5.60

$6.09

52-Week Range:

$5.60

$12.14

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name

Relay Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

617-370-8837

Address

399 BINNEY STREET, CAMBRIDGE

Employee

304

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

RLAY's Discussions on Twitter

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-20-23	Upgrade	Jefferies	Underperform → Hold
Apr-19-23	Upgrade	Raymond James	Outperform → Strong Buy
Apr-13-23	Initiated	Raymond James	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Sep-30-22	Initiated	Barclays	Equal Weight
Sep-02-22	Initiated	Stifel	Buy
Jun-06-22	Initiated	Jefferies	Underperform
Feb-01-22	Initiated	Berenberg	Buy
Jul-21-21	Initiated	BofA Securities	Buy
Dec-15-20	Reiterated	H.C. Wainwright	Buy
Dec-08-20	Initiated	JMP Securities	Mkt Outperform
Nov-05-20	Initiated	H.C. Wainwright	Buy
Aug-10-20	Initiated	Cowen	Outperform
Aug-10-20	Initiated	Goldman	Buy
Aug-10-20	Initiated	Guggenheim	Buy
Aug-10-20	Initiated	JP Morgan	Neutral

View All

Relay Therapeutics Inc Stock (RLAY) Latest News

Nov 04, 2024

Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts - Investing.com India

Oct 31, 2024

Oct 30, 2024

Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts By Investing.com - Investing.com South Africa

Oct 30, 2024

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 - The Manila Times

Oct 30, 2024

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, - EIN News

Oct 30, 2024

Oct 29, 2024

Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapy - Barchart

Oct 29, 2024

Oct 28, 2024

Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses - Yahoo Finance

Oct 28, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Oct 28, 2024

Oct 25, 2024

Several Relay Therapeutics Insiders Sell Shares Sending Potential Negative Signal - Simply Wall St

Oct 25, 2024

Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com Canada

Oct 25, 2024

Oct 24, 2024

Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase By Investing.com - Investing.com South Africa

Oct 24, 2024

Oct 16, 2024

Financial Snapshot: Analyzing Relay Therapeutics Inc (RLAY)’s Key Ratio Metrics - The Dwinnex

Oct 16, 2024

Oct 15, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest Update - MarketBeat

Oct 15, 2024

Oct 14, 2024

How did Relay Therapeutics Inc (RLAY) fare last session? - US Post News

Oct 14, 2024

Relay Therapeutics (NASDAQ:RLAY) Receives Buy Rating from HC Wainwright - MarketBeat

Oct 14, 2024

Relay Therapeutics stock holds price target on FDA approval By Investing.com - Investing.com UK

Oct 14, 2024